Allarity Therapeutics Inc (ALLR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Allarity Therapeutics Inc stock (ALLR) is currently trading at $1.12. Allarity Therapeutics Inc PE ratio is 0.21. Analyst consensus price target for ALLR is $9.25. WallStSmart rates ALLR as Sell.
- ALLR PE ratio analysis and historical PE chart
- ALLR PS ratio (Price-to-Sales) history and trend
- ALLR intrinsic value — DCF, Graham Number, EPV models
- ALLR stock price prediction 2025 2026 2027 2028 2029 2030
- ALLR fair value vs current price
- ALLR insider transactions and insider buying
- Is ALLR undervalued or overvalued?
- Allarity Therapeutics Inc financial analysis — revenue, earnings, cash flow
- ALLR Piotroski F-Score and Altman Z-Score
- ALLR analyst price target and Smart Rating
Allarity Therapeutics Inc
📊 No data available
Try selecting a different time range
ALLR Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Allarity Therapeutics Inc (ALLR)
ALLR trades at a significant discount to its Graham intrinsic value of $39.10, offering a 98% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Allarity Therapeutics Inc (ALLR) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Allarity Therapeutics Inc (ALLR) Key Strengths (1)
Trading at 1.43x book value, attractively priced
Supporting Valuation Data
Allarity Therapeutics Inc (ALLR) Areas to Watch (3)
Company is destroying shareholder value
Very low institutional interest at 3.73%
Micro-cap company with very limited liquidity and high volatility
Allarity Therapeutics Inc (ALLR) Detailed Analysis Report
Overall Assessment
This company scores 14/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 8.0/10) while 3 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.43) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Institutional Own., Market Cap. Profitability pressure is visible in Return on Equity at -150.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -150.60% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ALLR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ALLR's Price-to-Sales ratio of 120.43x trades 35% below its historical average of 184x (39th percentile). The current valuation is 90% below its historical high of 1255.67x set in Dec 2021, and 448% above its historical low of 21.97x in Aug 2024.
WallStSmart Analysis Synopsis
Data-driven financial summary for Allarity Therapeutics Inc (ALLR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Allarity Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Allarity Therapeutics Inc.
Bottom Line
Allarity Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 11:30:26 AM
About Allarity Therapeutics Inc(ALLR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Allarity Therapeutics A / S develops various therapeutic candidates for the treatment of cancer using complementary drug-specific diagnostics (cDx) generated by its drug response prediction technology. The company is headquartered in Horsholm, Denmark.